Faculty of Physics - University of Bucharest

UNIVERSITY OF BUCHAREST
FACULTY OF PHYSICS

Guest
2024-11-22 1:44

HOME CONFERENCES SEARCH LOGIN NEW USER IMAGES

Conference: Bucharest University Faculty of Physics 2018 Meeting

Section: Biophysics; Medical Physics

Title:

Luteolin anticancer activity studied in carcinoma and sarcoma cells

Authors:

Cristina CONSTANTIN (1), Claudia CHILOM (1), Mihaela BACALUM (2)

Affiliation:

1) Department of Electricity, Solid Physics and Biophysics, Faculty of Physics, University of Bucharest, Măgurele, Romania

2) Department of Life and Environmental Physics, “Horia Hulubei” National Institute of Physics and Nuclear Engineering, Măgurele, Romania

E-mail

bmihaela@nipne.ro

Keywords:

Luteolin, anticancer effect, cell viability, apoptosis

Abstract:

The anti-oxidant, anti-inflammatory and anti-carcinogenic properties of Luteolin [1, 2] are being investigated more and more frequently in recent years. Previous studies reported that Lutelolin alters the expression of key components in the tumor cell metabolism pathways, thus inducing cell cycle inhibition and apoptosis [2, 3]. Luteolin's anticancer effects are manifested by apoptosis, but other mechanisms, such as cell cycle inhibition and antiangiogenesis [4, 5], have been described. In this study, the mechanism of the anticancer effect of Luteolin against carcinoma and sarcoma cells was investigated. Four cell lines: one normal cell line (L929 - mouse fibroblasts) and three cancer cell lines (Hep G2 - human hepatocellular carcinoma, HT-29 - human colorectal adenocarcinoma, and MG-63 - human osteosarcoma) were tested in vitro. In a first step, the cell viability using the MTS assay, for cells treated with Luteolin in different concentration (0 - 250 µM) for 24 h was evaluated. The results showed that the most resistant to Luteolin treatment were the HT-29 cells. In the second step, we investigated the mechanism of cell death at two concentrations of Luteolin (10 and 100 µM). We found that Luteolin induces apoptosis in both carcinoma and sarcoma cells.

References:

[1] G. Seelinger, I. Merfort, U. Wölfle, C. M. Schemppet et al., Anti-carcinogenic Effects of the Flavonoid Luteolin, Molecules, 13(10):2628-2651, 2008

[2] K. Selvendiran, H. Koga, T. Ueno, T. Yoshida, M. Maeyama, T. Torimura, H. Yano, M. Kojiro, and M. Sata, Luteolin Promotes Degradation in Signal Transducer and Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the Antitumor Potential of Flavonoids, Cancer Res., 66(9):4826-4834, 2006.

[3] H. Ueda, H. Oku, M. Iinuma, K. Ishiguro, Antianaphylactic and Antipruritic Effects of the Flowers of Impatiens Textori MIQ, Biol. Pharm. Bull., 26:560-5633, 2003

[4] F. Casagrande and J. M. Darbon, Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1, Biochem. Pharmacol., 61:1205-1215, 2001

[5] E. Bagli, M. Stefaniotou, L. Morbidelli, M. Ziche, K. Psillas, C. Murphy, and T. Fotsis, Luteolin Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis; Inhibition of Endothelial Cell Survival and Proliferation by Targeting Phosphatidylinositol 3’-Kinase Activity, Cancer Res., 64: 7936–7946, 2004

Acknowledgement:

This work was supported by the grants of the Romanian National Authority for Scientific Research, CNDI-UEFISCDI, Projects number PN 16420203, PN 18090202.